December 2nd 2023
In a recent post hoc analysis of the Study C021 trial, findings support the idea that early adjustments to concomitant antiseizure medications enhance the retention of cenobamate, an FDA-approved treatment for focal seizures.
Patient, Provider, and Caregiver Connection™: Challenges in Diagnosis and Management for Patients with ADHD During the COVID-19 Pandemic
View More
Expert Illustrations & Commentaries™: A Family Physicians’ Guide to Migraine Treatment – Emerging Therapies and Evolving Paradigms
View More
PER® Postgame™: MS Meeting Updates – Integrating the Latest Data to Optimize Care in the COVID-19 Era
View More
Medical Crossfire®: What Strategies Can the Care Team Implement to Optimize the Management of Pediatric Patients with NF1?
View More
Patient, Provider, & Caregiver Connection: Individualizing Care in Multiple Sclerosis – Understanding Patient Challenges and the Role of Innovative Treatment
View More
FAQs in MS: Exploring Provocative Questions From MS Meeting Updates
View More
BURST CME™: Taking ALS Management to the Next Level
View More
The Expanding Role of Fluid Biomarkers in the Diagnosis and Management of Patients With Alzheimer Disease
View More
PREDICT-PD Algorithm Shows Ability to Identify Early Motor Dysfunction, Parkinsonism
PREDICT-PD, a low intensity and cost-efficient assessment, was able to estimate the occurrence of motor disturbances in the future, in particular sub-threshold parkinsonism and bradykinesia.
World Movement Disorders Day: Octave’s Impact on Parkinson Disease Research
November 29th 2023Jim Eubanks, PhD, national director of medical affairs at Octave, provided thoughts on the company’s $10 million grant from The Michael J. Fox Foundation for Parkinson’s Research and highlighted the importance of awareness for movement disorders like Parkinson disease.
Building on Momentum: Overviewing Ongoing Efforts from the Alzheimer’s Association
Heather Synder, PhD, vice president of medical and scientific relations at the Alzheimer’s Association, gave thoughts on the recently concluded CTAD conference and how the organization plans to carry the positive momentum in the field.
NeuroVoices: Emad Estemalik, MD, on Pioneering a New Age of Migraine Care
The director of the headache section at Cleveland Clinic’s Neurological Institute provided thoughts on how recent advances have propelled migraine care, treatment possibilities behind prevention, and emerging research targets.
FDA Warns of Serious Adverse Effects for Using Levetiracetam and Clobazam in Epilepsy
November 28th 2023In a new announcement, the FDA warns patients to immediately seek out medical attention if unexplained rash, fever, or swollen lymph nodes develop when using the antiseizure medications levetiracetam and clobazam.
Considerations Amid the Ever-Changing Field of Alzheimer Disease
Alvaro Pascual-Leone, MD, PhD, director of the Berenson-Allen Center for Noninvasive Brain Stimulation at Beth Israel Deaconess Medical Center, provided commentary on the ways Alzheimer disease treatment has changed and how clinicians will need to adapt in the coming years.
NRTX-1001 Shows Seizure Suppression in Preclinical Drug-Resistant Focal Epilepsy Models
November 27th 2023Neurona Therapeutics’ NRTX-1001, a regenerative neural cell therapy derived from human stem cells, showed promise in potentially suppressing seizures in patients with drug-resistant mesial temporal lobe epilepsy.
Biosimilars Enter the Multiple Sclerosis Treatment Paradigm
A panel of experts provide commentary on a range of topics regarding the integration of biosimilars in the management of multiple sclerosis, including the supporting data behind these agents and how the clinical community can adapt.
Adherence to Multiple Sclerosis Disease-Modifying Therapy Lowers Risk of Relapse, Severe Relapse
The study added to the evidence base for recommending adherence to treatment with disease-modifying therapies in clinical practice, a key element for reducing moderate or severe relapse rate.
Medical Gaslighting: Multiple Sclerosis’ Dirty Little Secret?
November 24th 2023The effect of gaslighting on patients can result in serious harms, and although it is potentially common in the MS care continuum, whether it is deliberate or an institutional problem, it must be called out by providers.